Gibson Diagnostic Labs, LLC

Gibson Diagnostic Labs, LLC was paid $186K by Medicaid between Jan 2018 and Aug 2023, across 49 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 41% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#126 of 436

Median peer was paid$17K

This provider vs. median11×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,555	$3K
2019	4,298	$1K
2020	16,303	$41K
2021	15,523	$51K
2022	6,608	$86K
2023	959	$4K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	41%	2,591	1,530	$76K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	27%	4,259	2,396	$51K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	8.2%	1,635	932	$15K
87631		6.0%	694	585	$11K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	4.4%	946	877	$8K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.8%	2,848	2,716	$5K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.7%	4,977	4,678	$3K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	1.2%	2,336	1,348	$2K
87481		1.2%	2,173	1,657	$2K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	668	603	$1K
87500		<1%	1,863	1,595	$1K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	2,105	1,808	$935.32

37 more codes

87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	217	$928.65
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,627	$904.43
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,616	$904.43
87640		<1%	2,388	$820.34
87486		<1%	1,705	$809.61
87581		<1%	1,536	$773.13
87541		<1%	1,483	$745.12
87641		<1%	1,935	$699.90
87653		<1%	1,628	$667.08
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	193	$290.00
87561		<1%	629	$270.89
87556		<1%	369	$244.39
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	317	$145.72
87529		<1%	285	$99.56
87563		<1%	190	$69.33
87496		<1%	190	$49.78
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	28	$48.76
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	58	$23.46
81407		0%	130	$0.00
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	0%	36	$0.00
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	0%	121	$0.00
87900		0%	28	$0.00
81161		0%	15	$0.00
87511		0%	36	$0.00
81404		0%	727	$0.00
86756		0%	71	$0.00
87150		0%	259	$0.00
81238		0%	14	$0.00
81408		0%	279	$0.00
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	0%	71	$0.00
81406		0%	423	$0.00
81286		0%	45	$0.00
81405		0%	368	$0.00
81414		0%	14	$0.00
81401		0%	92	$0.00
81413		0%	14	$0.00
81411		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSHAH, AZMAT (OWNER)